Company Team Projects Media Contact


Investing in biomedical discoveries

LASCCO SA is a biomedical-technology development private company based in Geneva, Switzerland. The primary objective of LASCCO is to bring promising early-stage biomedical technologies – therapeutics and diagnostics – developed in research institutes to the attention of the pharmaceutical industry.




Combioxin to present CAL02's clinical data at the FDA's Workshop on the Development of Non-Traditional Therapies for Bacterial Infections, at FDA's White Oak campus on Aug 21-22, 2018

Combioxin selected for oral presentation on the results of the first CAL02 clinical trial at the ESICM Annual Congress in Paris on Oct 24, 2018

Positive Topline Results from First-in-Man Trial with CAL02 in the Treatment of Severe Pneumonia - Apr 17, 2018